Table 1.
Patient characteristics of the cohorts of interest.
| EU cohort |
UK cohort |
χ2 test |
|
|---|---|---|---|
| N = 924 (%) | N = 468 (%) | p-value | |
| Gender | |||
| Male | 451 (48.86) | 287 (61.72) | <0.0001 |
| Female | 472 (51.14) | 1778 (38.28) | |
| Missing | 4 | ||
| Age | |||
| <65 years | 382 (41.75) | 151 (32.26) | 0.0006 |
| ≥65 years | 533 (58.25) | 317 (67.74) | |
| Missing | 9 | ||
| Number of comorbidities | |||
| 0–1 | 420 (45.45) | 175 (37.39) | 0.0041 |
| ≥2 | 504 (54.55) | 293 (62.61) | |
| Missing | 0 | ||
| Smoking history | |||
| Never-smokers | 407 (44.97) | 192 (41.29) | 0.8355 |
| Former/current smokers | 383 (42.32) | 176 (37.85) | |
| Missing | 234 | ||
| Cancer site | |||
| Breast | 219 (23.70) | 58 (12.39) | <0.0001 |
| Gastrointestinal | 167 (18.07) | 92 (19.66) | |
| Gynaecological/genitourinary | 132 (14.29) | 146 (31.20) | |
| Haematological | 172 (18.61) | 53 (11.32) | |
| Lung | 118 (12.77) | 58 (12.64) | |
| Other | 116 (12.55) | 61 (13.03) | |
| Missing | 0 | ||
| Tumour stage | |||
| Local/locoregional | 390 (42.21) | 294 (62.82) | <0.0001 |
| Advanced | 380 (41.13) | 151 (32.26) | |
| Missing | 177 | ||
| Tumour status | |||
| Remission/non-measurable disease | 299 (32.97) | 150 (32.97) | 0.9996 |
| Active malignancy | 608 (67.03) | 305 (67.03) | |
| Missing | 30 | ||
| Anticancer therapy at COVID-19 diagnosis | |||
| No | 371 (40.55) | 278 (61.64) | <0.0001 |
| Yes | 544 (59.55) | 173 (38.36) | |
| Missing | 26 | ||
| COVID-19 therapy (any) | |||
| No | 224 (25.31) | 163 (39.47) | <0.0001 |
| Yes | 661 (74.69) | 250 (60.53) | |
| Missing | 94 | ||
| Complicated COVID-19 | |||
| No | 367 (39.72) | 179 (8.25) | 0.5955 |
| Yes | 557 (60.28) | 289 (61.75) | |
| Missing | 0 | ||
COVID-19, coronavirus disease 2019; EU, Europe; UK, United Kingdom.